Abstract
Astrocytes are the most abundant cells in the brain and play an important role in the homeostasis and maintenance of the brain. Furthermore, astrocytes play a key role in brain protection and in functional recovery from injuries. Impairment in astrocytes activity may promote neurodegeneration and, eventually, retraction of neuronal synapses, which leads to cognitive deficits found in neurodegenrative diseases, such as Alzheimers disease. Alzheimers disease (AD) is the most common type of dementia affecting more than 18 million people worldwide. The main cause of AD is generally attributed to the increased production and accumulation of amyloid-β (Aβ), in association with neurofibrillary tangle (NFT) formation. In AD patients brain, reactive astrocytes are integral components of neuritic plaques. Astrocytic activation seems to be particularly prominent around Aβ deposits both in the brain parenchyma and in the cerebrovasculature. Furthermore, recent evidence from AD patients suggests that pathological changes in the morphology of astrocyte occur prior to the appearance of Aβ plaques. The focus of this review is on astrocytic cells and their role in the progression of AD.
Keywords: Astrocyte, Alzheimer's disease, imflammation, neuroprotection, homeostasis, brain protection, amyloid-β, astrogliosis, astrocyte atrophy, neuroinflammation
Current Signal Transduction Therapy
Title: Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Volume: 7 Issue: 1
Author(s): Tal Iram and Dan Frenkel
Affiliation:
Keywords: Astrocyte, Alzheimer's disease, imflammation, neuroprotection, homeostasis, brain protection, amyloid-β, astrogliosis, astrocyte atrophy, neuroinflammation
Abstract: Astrocytes are the most abundant cells in the brain and play an important role in the homeostasis and maintenance of the brain. Furthermore, astrocytes play a key role in brain protection and in functional recovery from injuries. Impairment in astrocytes activity may promote neurodegeneration and, eventually, retraction of neuronal synapses, which leads to cognitive deficits found in neurodegenrative diseases, such as Alzheimers disease. Alzheimers disease (AD) is the most common type of dementia affecting more than 18 million people worldwide. The main cause of AD is generally attributed to the increased production and accumulation of amyloid-β (Aβ), in association with neurofibrillary tangle (NFT) formation. In AD patients brain, reactive astrocytes are integral components of neuritic plaques. Astrocytic activation seems to be particularly prominent around Aβ deposits both in the brain parenchyma and in the cerebrovasculature. Furthermore, recent evidence from AD patients suggests that pathological changes in the morphology of astrocyte occur prior to the appearance of Aβ plaques. The focus of this review is on astrocytic cells and their role in the progression of AD.
Export Options
About this article
Cite this article as:
Iram Tal and Frenkel Dan, Targeting the Role of Astrocytes in the Progression of Alzheimers Disease, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278232
DOI https://dx.doi.org/10.2174/157436212799278232 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design Aging and DNA Methylation
Current Chemical Biology BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Current Alzheimer Research 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review
Combinatorial Chemistry & High Throughput Screening HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Ginkgo Biloba Extract in an Animal Model of Parkinson’s Disease: A Systematic Review
Current Neuropharmacology Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research